COVID-19: In Vitro Diagnostic Testing - (0557) — MM 0557 | CIGNA Coverage Update

Cigna modified MM 0557 for COVID-19 in vitro diagnostic testing, effective January 16, 2026. Here's what changes for billing teams.

Cigna Healthcare updated Coverage Policy MM 0557, which governs molecular, antigen, and antibody testing for SARS-CoV-2. The update aligns the policy with 2024 CDC and IDSA guidance and 2023 FDA statements. Fourteen CPT and HCPCS codes are in scope — including 87635 for PCR-based nucleic acid detection, 87426 and 87428 for antigen testing, and the antibody codes 86769, 86328, and 86413. If your lab or practice bills any of these, the effective date of January 16, 2026 is already live.

Quick-Reference Table

Cigna COVID-19 In Vitro Diagnostic Testing Coverage Criteria and Medical Necessity Requirements 2026

The Cigna COVID-19 in vitro diagnostic testing coverage policy covers three distinct test categories: molecular tests, antigen tests, and antibody (serology) tests. Each has different medical necessity standards. Getting the category wrong — or mixing up the appropriate use cases — is where most claim denial risk lives.

Molecular tests detect the genetic material of SARS-CoV-2. CPT 87635 is the primary code here, and HCPCS U0001 and U0002 cover CDC and non-CDC RT-PCR panels respectively. CPT 87913 covers genotype analysis by nucleic acid — relevant when variant identification is clinically indicated. These tests carry medical necessity coverage when criteria in the applicable policy section are met.

Antigen tests detect protein fragments from the virus. CPT 87426 covers single-analyte antigen detection. CPT 87428 covers combination antigen testing — for example, a panel that tests for both SARS-CoV-2 and influenza simultaneously. Both codes fall under the same coverage position: medically necessary when criteria are met.

Antibody and serology tests are where billing teams most often get tripped up. The policy is clear: antibody testing does not diagnose active COVID-19. Cigna covers codes 0224U, 0226U, 86328, 86408, 86409, 86413, and 86769 for antibody and neutralizing antibody testing — but the indication drives coverage. Public health surveillance and exposure assessment can justify these codes. Billing 86769 with a diagnosis of active COVID-19 when the clinical picture actually called for 87635 is a direct path to denial.

The policy explicitly updates its clinical references to FDA guidance from 2023, CDC guidance from 2024, and IDSA recommendations from 2022, 2023, and 2024. This matters because prior authorization decisions and medical necessity reviews will now be benchmarked against those updated sources. If you're defending a claim on appeal, pull those references.

Pooled sample testing is in scope for this coverage policy. Individual result reporting and multi-person pooled reporting are both addressed. Nucleic acid pathogen testing by panel, however, falls outside this policy entirely — Cigna handles that under CP 0530. If your lab runs multi-pathogen respiratory panels that include SARS-CoV-2, don't bill under MM 0557. Route those claims through CP 0530 billing guidelines instead.

CPT 99199 — the unlisted special service code — appears in scope here. Its presence signals that Cigna accounts for novel or non-standard COVID testing configurations. That code requires strong documentation to survive review.

Coverage Indications at a Glance

Cigna COVID-19 Testing Billing Guidelines and Action Items 2026

The real issue with MM 0557 is ICD-10 pairing. The policy lists 14 diagnosis codes — and the difference between Z11.52 (screening for COVID-19), Z20.828 (exposure), and a clinical diagnosis code determines both coverage and reimbursement. Most billing errors here come from defaulting to Z11.52 when a more specific code applies.

CPT, HCPCS, and ICD-10 Codes for COVID-19 In Vitro Diagnostic Testing Under MM 0557

Covered CPT Codes (When Selection Criteria Are Met)

Covered HCPCS Codes (When Selection Criteria Are Met)

Key ICD-10-CM Diagnosis Codes